Paolo Bottau

Dr. Paolo Bottau

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2019 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
Carlo CaffarelliCarlo Caffarelli
Carlo Caffarelli
FPFrancesco Paravati
Francesco Paravati
MHMay El Hachem
May El Hachem
MDmarzia duse
marzia duse
MBMarcello Bergamini
Marcello Bergamini
FCFabio Cardinale
Fabio Cardinale
The aim of this guidance is to provide recommendations to clinicians and other interested parties on chronic urticaria in children. The Italian Society for Pediatrics (SIP), the Italian Society for Allergy and Immunology (SIAIP), the Italian Society for Pediatric dermatology (SIDerP) convened a multidisciplinary panel that prepared clinical guidelines for diagnosis and management of chronic urticaria in childhood. Key questions on epidemiology, natural history, diagnosis, and management were developed. The literature was systematically searched and evaluated, recommendations were rated and algorithms for diagnosis and treatment were developed. The recommendations focus on identification of diseases and comorbidities, strategies to recognize triggering factors, improvement of treatment by individualized care.

18 August 2019 in Medicina
Verified
Journal Article
Open access
PDF file
ECElisabetta Calamelli
Elisabetta Calamelli
LLLucia Liotti
Lucia Liotti
IBIsadora Beghetti
Isadora Beghetti
VPValentina Piccinno
Valentina Piccinno
LSlaura serra
laura serra
PBPaolo Bottau
Paolo Bottau
Component-resolved diagnostics (CRD) in food allergies is an approach utilized to characterize the molecular components of each allergen involved in a specific IgE (sIgE)-mediated response. In the clinical practice, CRD can improve diagnostic accuracy and assist the physician in many aspects of the allergy work-up. CRD allows for discriminatory co-sensitization versus cross-sensitization phenomena and can be useful to stratify the clinical risk associated with a specific sensitization pattern, in addition to the oral food challenge (OFC). Despite this, there are still some unmet needs, such as the risk of over-prescribing unnecessary elimination diets and adrenaline auto-injectors. Moreover, up until now, none of the identified sIgE cutoff have shown a specificity and sensitivity profile as accurate as the OFC, which is the gold standard in diagnosing food allergies. In light of this, the aim of this review is to summarize the most relevant concepts in the field of CRD in food allergy and to provide a practical approach useful in clinical practice.

17 November 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
Carlo CaffarelliCarlo Caffarelli
Carlo Caffarelli
DMDora Di Mauro
Dora Di Mauro
Carla MastrorilliCarla Mastrorilli
Carla Mastrorilli
PBPaolo Bottau
Paolo Bottau
FCFrancesca Cipriani
Francesca Cipriani
Giampaolo RicciGiampaolo Ricci
Giampaolo Ricci
The rise of food allergy in childhood, particularly among developed countries, has a significant weight on public health and involves serious implications for patients’ quality of life. Even if the mechanisms of food tolerance and the complex interactions between the immune system and environmental factors are still mainly unknown, pediatricians have worldwide implemented preventive measures against allergic diseases. In the last few decades, the prevention of food allergy has tracked various strategies of complementary feeding with a modification of international guidelines from delayed introduction to early weaning. Current evidence shows that complementary foods, including allergenic ones, should be introduced into diet after four months, or even better, following World Health Organization advice, around six months irrespective of risk for allergy of the individual. The introduction of peanut is recommended before 12 months of age among infants affected by severe eczema and/or egg allergy to diminish the occurrence of peanut allergy in countries with high peanut consumption. The introduction of heated egg at 6–8 months of age may reduce egg allergy. Infants at high risk of allergy similarly to healthy children should introduce complementary foods taking into account family and cultural preferences.

14 April 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PBPaolo Bottau
Paolo Bottau
LLLucia Liotti
Lucia Liotti
ELEleonora Laderchi
Eleonora Laderchi
APAlessandra Palpacelli
Alessandra Palpacelli
ECElisabetta Calamelli
Elisabetta Calamelli
SCSalvatore Cazzato
Salvatore Cazzato
Acute Viral Bronchiolitis is one of the leading causes of hospitalization in the first 12–24 months of life. International guidelines on the management of bronchiolitis broadly agree in recommending a minimal therapeutic approach, not recommending the use of bronchodilators. Guidelines, generally, consider bronchiolitis as a “unique disease” and this runs the risk of not administering therapy in some patients who could benefit from the use of bronchodilators, for instance, in those who will develop asthma later in their life and face first episode in the age of bronchiolitis. Today, there is growing evidence that bronchiolitis is not a single illness but can have different “endotypes” and “phenotypes,” based on age, personal or family history of atopy, etiology, and pathophysiological mechanism. There is evidence that some phenotypes of bronchiolitis are more strongly associated with asthma features and are linked to higher risk for asthma development. In these populations, possible use of bronchodilators might have a better impact. Age seems to be the main feature to suggest a good response to a bronchodilator-trial, because, among children > 6 months old with bronchiolitis, the presence of a subset of patients with virus-induced wheezing or the first episode of asthma is more likely. While waiting for new research to define the relationship between therapeutic options and different phenotypes, a bronchodilator-trial (using short-acting β2 agonists with metered-dose inhalers and valved holding chambers) seems appropriate in every child with bronchiolitis and age > 6 months.

12 May 2020 in Medicina
Verified
Journal Article
Open access
PDF file
Francesca MoriFrancesca Mori
Francesca Mori
FSFrancesca Saretta
Francesca Saretta
ABAnnamaria Bianchi
Annamaria Bianchi
GCGiuseppe Crisafulli
Giuseppe Crisafulli
SCSilvia Caimmi
Silvia Caimmi
Carlo CaffarelliCarlo Caffarelli
Carlo Caffarelli
Biologic drugs are widely used in pediatric medicine. Monoclonal antibodies (mAbs) in particular are a therapeutic option for rheumatic, autoinflammatory and oncologic diseases. Adverse drug reactions and hypersensitivity reactions (HSR) to mAbs may occur in children. Clinical presentation of HSRs to mAbs can be classified according to phenotypes in infusion-related reactions, cytokine release syndrome, both alpha type reactions and type I (IgE/non-IgE), type III, and type IV reactions, all beta-type reactions. The aim of this review is to focus on HSRs associated with the most frequent mAbs in childhood, with particular attention to beta-type reactions. When a reaction to mAbs is suspected a diagnostic work-up including in-vivo and in-vitro testing should be performed. A drug provocation test is recommended only when no alternative drugs are available. In selected patients with immediate IgE-mediated drug allergy a desensitization protocol is indicated. Despite the heavy use of mAbs in childhood, studies evaluating the reliability of diagnostic test are lacking. Although desensitization may be effective in reducing the risk of reactions in children, standardized pediatric protocols are still not available.

27 February 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ABAnnamaria Bianchi
Annamaria Bianchi
RVRocco Valluzzi
Rocco Valluzzi
GCGiuseppe Crisafulli
Giuseppe Crisafulli
PBPaolo Bottau
Paolo Bottau
SCSilvia Maria Elena Caimmi
Silvia Maria Elena Caimmi
Carlo CaffarelliCarlo Caffarelli
Carlo Caffarelli
Drug-induced anaphylaxis in children is less common than in adults and primarily involves beta-lactams and nonsteroidal anti-inflammatory drugs. Epidemiological studies show variable prevalence, influenced by age, gender, and atopic diseases. The pathophysiology includes IgE-mediated reactions and non-IgE mechanisms, like cytokine release reactions. We address drug-induced anaphylaxis in children, focusing on antibiotics, nonsteroidal anti-inflammatory drugs, neuromuscular blocking agents, and monoclonal antibodies. Diagnosis combines clinical criteria with in vitro, in vivo, and drug provocation tests. The immediate management of acute anaphylaxis primarily involves the use of adrenaline, coupled with long-term strategies, such as allergen avoidance and patient education. Desensitization protocols are crucial for children allergic to essential medications, particularly antibiotics and chemotherapy agents.